Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

[Management of chronic hepatitis C in 2012 in Belgium].

Moreno C, Deltenre P.

Rev Med Brux. 2012 Sep;33(4):223-7. Review. French.

PMID:
23091925
2.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
3.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

4.

[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].

Crespo G, Lens S.

Gastroenterol Hepatol. 2012 May;35(5):337-43. doi: 10.1016/j.gastrohep.2011.12.005. Epub 2012 Feb 19. Spanish.

PMID:
22349607
5.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

6.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
7.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
8.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
9.

Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?

Michielsen P, Ho E, Francque S.

Minerva Gastroenterol Dietol. 2012 Mar;58(1):65-79. Review.

PMID:
22419005
10.

Future treatment of patients with HCV cirrhosis.

Bourlière M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Benali S, Adhoute X, Castellani P.

Liver Int. 2012 Feb;32 Suppl 1:113-9. doi: 10.1111/j.1478-3231.2011.02702.x. Review.

PMID:
22212581
11.

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

Shiffman ML, Esteban R.

Liver Int. 2012 Feb;32 Suppl 1:54-60. doi: 10.1111/j.1478-3231.2011.02718.x. Review.

PMID:
22212573
12.

[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].

Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.

Z Gastroenterol. 2012 Jan;50(1):57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5. Review. German.

PMID:
22222799
13.

New treatments for chronic hepatitis C virus infection.

Corouge M, Pol S.

Med Mal Infect. 2011 Nov;41(11):579-87. doi: 10.1016/j.medmal.2011.04.003. Epub 2011 Jul 20. Review.

PMID:
21764234
14.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

15.

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.

Asselah T, Marcellin P.

Liver Int. 2012 Feb;32 Suppl 1:88-102. doi: 10.1111/j.1478-3231.2011.02699.x. Review.

PMID:
22212578
16.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
17.

Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients.

Fontaine H, Pol S.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S59-63. doi: 10.1016/S2210-7401(11)70009-2. Review.

PMID:
22248696
18.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
19.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
20.

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.

Teixeira R, Nascimento Yde A, Crespo D.

Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9. Review.

Items per page

Supplemental Content

Write to the Help Desk